Cabozantinib with nivolumab approved in EU for first-line treatment for patients with advanced renal cell carcinoma

Approval was based on CheckMate -9ER trial, which found that the combination doubled progression-free survival and objective response rate while significantly improving overall survival vs sunitinib.

Biospace Inc.